1-3 of 3
Jana Hoffmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.

Martin C. Mueller, MD, Philipp Erben, MD, Thomas Ernst, MD, Michelle Giehl, PhD, Thomas Schenk, MD, Jana Hoffmann, Stephanie Lauber, MD, Jens Kruth, MD, Benjamin Hanfstein, MD, Eric Bleickardt, MD, Claude Nicaise, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2007) 110 (11): 319.
https://doi.org/10.1182/blood.V110.11.319.319
Published: 2007
Journal Articles

Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.

Martin C. Müller, MD, Philipp Erben, MD, Thomas Schenk, MD, Stephanie Lauber, MD, Jens Kruth, MD, Jana Hoffmann, Thomas Ernst, MD, Tanja Lahaye, MD, Georgia Metzgeroth, MD, Michael Acevedo, PhD, Claude Nicaise, MD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2006) 108 (11): 748.
https://doi.org/10.1182/blood.V108.11.748.748
Published: 2006
Journal Articles

Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure.

Andreas Hochhaus, MD, Philipp Erben, MD, Susan Branford, PhD, Jerald Radich, MD, D.W. Kim, MD, Giovanni Martinelli, MD, Giuseppe Saglio, MD, Martin C. Mueller, MD, Jana Hoffmann, Francesca Palandri, Simona Soverini, MD, Timothy Hughes, MD, Yaping Shou, MD PhD, Aaron Weitzman, MD, Michele Baccarani, MD
Journal: Blood
Blood (2006) 108 (11): 749.
https://doi.org/10.1182/blood.V108.11.749.749
Published: 2006